El Patent Pool estimula las perspectivas de medicamentos anti-VIH con una primera Licencia 13/07/2011 by William New, Intellectual Property Watch 3 Comments El Medicines Patent Pool y la compañía farmacéutica Gilead Sciences ha anunciado hoy un acuerdo de licencia para permitir la producción medicamentos clave para el combate contra el VIH a un menor costo y en una formulación más fácil de usar, haciéndolos más accesibles a los países en desarrollo.. El acuerdo se extiende al uso de tratamientos para la hepatitis B por primera vez.
Does Introduction Of A Utility Model Protection Regime Make Sense In India? 13/07/2011 by Intellectual Property Watch 2 Comments India has at least seven diverse intellectual property (IP) legislations related to protection already in place. Its focus should therefore arguably be directed – along the lines of many other IP jurisdictions – on more stringent enforcement modus operandi of the IP rights. Is there scope for introducing yet another IP legislation – the utility model protection law – in the Indian IP landscape and if so, what should be its scope and implication, asks Swarup Kumar.
Trans-Pacific Partnership Agreement: Did US Move Threaten Public Health? 12/07/2011 by Catherine Saez, Intellectual Property Watch 3 Comments Civil society groups say a leaked document from regional free trade negotiations between countries bordering the Pacific Ocean shows the United States favouring giant pharmaceutical companies at the expense of public health. Separately, the tobacco industry is allegedly also trying to push for a clause to prevent plain packaging.
Medicines Patent Pool Boosts HIV Drug Prospects With First Licence 12/07/2011 by William New, Intellectual Property Watch 4 Comments The Medicines Patent Pool and pharmaceutical company Gilead Sciences today announced a breakthrough licence agreement to allow for the production of key HIV medicines at lower cost and in an easier-to-use formulation, making them more accessible to developing countries. The agreement also opens up the use of treatments for Hepatitis B for the first time.
WIPO Ventures Into Global Debate On Climate Change 08/07/2011 by Catherine Saez, Intellectual Property Watch Leave a Comment The World Intellectual Property Organization is continuing its push to become involved in some of the biggest policy questions of the day with an international conference on climate change next week. This follows recent efforts on public health and food security.
UN Body Addresses Problems With IP Rights Within Europe 08/07/2011 by Intellectual Property Watch 3 Comments The United Nations Economic Commission for Europe (UNECE) is holding a two-day meeting to increase awareness of intellectual property rights throughout the region.
Non-Communicable Diseases Issue Energises Public Health Policymakers 07/07/2011 by William New, Intellectual Property Watch Leave a Comment Concern over non-communicable diseases – traditionally a more developed-country set of problems like diabetes – is energising the international public health policy community. But representatives of the public interest are still grappling with their response.
CERN Issues Open Hardware Licence For Electronic Designs 07/07/2011 by Intellectual Property Watch 1 Comment The European Organisaton for Nuclear Research (CERN) today issued an open hardware licence for electronic designs, following its principle of “open science.”
Spain, Italy File Opposition To EU Unitary Patent 07/07/2011 by Intellectual Property Watch 2 Comments The governments of Spain and Italy have filed complaints with the European Court of Justice calling for the annullment of a March European Council decision to create an EU unitary patent.
UNAIDS Praises India’s Vow Not To Negotiate Away Generics 06/07/2011 by Intellectual Property Watch Leave a Comment The joint United Nations Programme on HIV/AIDS (UNAIDS) today praised the commitment made by India’s Commerce Minister not to negotiate stronger intellectual property rights provisions that could undermine India’s global leadership in the production of affordable generic AIDS drugs.